Symbols / ELDN
ELDN Chart
About
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 195.09M |
| Enterprise Value | 43.37M | Income | -82.67M | Sales | — |
| Book/sh | 1.52 | Cash/sh | 1.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31 | IPO | — |
| P/E | — | Forward P/E | -2.60 | PEG | — |
| P/S | — | P/B | 1.61 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 6.59 |
| Current Ratio | 6.74 | Debt/Eq | 0.79 | LT Debt/Eq | — |
| EPS (ttm) | -1.30 | EPS next Y | -0.94 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -44.22% |
| ROE | -95.49% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 79.63M |
| Shs Float | 54.44M | Short Float | 8.72% | Short Ratio | 8.33 |
| Short Interest | — | 52W High | 4.60 | 52W Low | 1.35 |
| Beta | 0.89 | Avg Volume | 831.78K | Volume | 2.11M |
| Target Price | $8.00 | Recom | None | Prev Close | $2.27 |
| Price | $2.45 | Change | 7.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$2.45
Latest analyst target
3. DCF / Fair value
$-8.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.45
Low
$4.00
High
$12.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-18 | main | Guggenheim | Buy → Buy | $8 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-07-25 | init | Craig-Hallum | — → Buy | $12 |
| 2024-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-05-07 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-10-24 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-09-27 | init | Noble Capital Markets | — → Outperform | $10 |
| 2023-08-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $9 |
| 2023-05-26 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2022-06-01 | main | SVB Leerink | — → Outperform | $26 |
| 2021-11-24 | main | HC Wainwright & Co. | — → Buy | $25 |
| 2021-04-27 | main | SVB Leerink | — → Outperform | $33 |
| 2021-03-23 | init | Cantor Fitzgerald | — → Overweight | $25 |
| 2021-02-08 | init | SVB Leerink | — → Outperform | $34 |
- 2-year transplant data: Eledon's tegoprubart shows no rejection in 8 patients - Stock Titan Fri, 23 Jan 2026 08
- Why Is Eledon Pharmaceuticals Stock (ELDN) Down 50% Today? - TipRanks Fri, 07 Nov 2025 08
- Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects - Yahoo Finance Sun, 09 Nov 2025 08
- With 51% ownership in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), institutional investors have a lot riding on the business - simplywall.st Sat, 18 Oct 2025 07
- Eledon Pharmaceuticals Initiates Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative ue, 11 Nov 2025 08
- Eledon Pharmaceuticals stock tumbles after mixed kidney transplant data - Investing.com Fri, 07 Nov 2025 08
- What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock - Nasdaq Fri, 23 May 2025 07
- 2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780% - Barchart.com ue, 23 Sep 2025 07
- Eledon Pharmaceuticals: Stock Surge Mystery - StocksToTrade Fri, 07 Nov 2025 08
- Eledon Pharmaceuticals Announces Proposed Underwritten - GlobeNewswire ue, 11 Nov 2025 08
- Guggenheim Lowers Price Target for ELDN While Maintaining Buy Ra - GuruFocus ue, 18 Nov 2025 08
- Eledon Pharma (NASDAQ: ELDN) prices $50M offering; adds 30-day underwriter option - Stock Titan Wed, 12 Nov 2025 08
- Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is largely controlled by institutional shareholders who own 51% of the company - Yahoo Finance hu, 09 Oct 2025 07
- Eledon Pharmaceuticals stock rises after positive islet transplant data - Investing.com ue, 18 Nov 2025 08
- Evaluating Eledon Pharmaceuticals (ELDN) Valuation Following Phase 2 BESTOW Results and Pipeline Progress - simplywall.st Mon, 10 Nov 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8575 | — | — | KATKIN KEITH A | Director | — | 2026-01-09 00:00:00 | D | nan |
| 1 | 3430 | — | — | MCBRIDE JOHN S | Director | — | 2026-01-09 00:00:00 | D | nan |
| 2 | 3430 | — | — | LEE JUNE YONG | Director | — | 2026-01-09 00:00:00 | D | nan |
| 3 | 3430 | — | — | ROBINSON JAMES A JR. | Director | — | 2026-01-09 00:00:00 | D | nan |
| 4 | 3430 | — | — | HILLSON JAN M.D. PH.D. | Director | — | 2026-01-09 00:00:00 | D | nan |
| 5 | 3430 | — | — | KIRK ALLAN | Director | — | 2026-01-09 00:00:00 | D | nan |
| 6 | 1927937 | — | Purchase at price 2.40 per share. | BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-09 00:00:00 | I | 4627049.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 6.49M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.06 |
| NormalizedEBITDA | -101.12M | 33.59M | 9.24M | -36.67M |
| TotalUnusualItems | 30.90M | -76.21M | -48.65M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 30.90M | -76.21M | -48.65M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -36.18M | -116.54M | -87.97M | -34.51M |
| ReconciledDepreciation | 359.00K | 374.00K | 373.00K | 195.00K |
| EBITDA | -70.22M | -42.63M | -39.41M | -36.67M |
| EBIT | -70.58M | -43.00M | -39.78M | -36.87M |
| NetInterestIncome | 0.00 | |||
| NormalizedIncome | -60.59M | -40.33M | -39.32M | -34.51M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -36.18M | -116.54M | -87.97M | -34.51M |
| TotalExpenses | 70.58M | 43.00M | 39.78M | 36.87M |
| TotalOperatingIncomeAsReported | -43.00M | -88.43M | -36.87M | |
| DilutedAverageShares | 48.54M | 24.62M | 14.29M | 14.82M |
| BasicAverageShares | 48.54M | 24.62M | 14.29M | 14.82M |
| DilutedEPS | -0.66 | -3.74 | -6.16 | -2.33 |
| BasicEPS | -0.66 | -3.74 | -6.16 | -2.33 |
| DilutedNIAvailtoComStockholders | -36.18M | -116.54M | -87.97M | -34.51M |
| NetIncomeCommonStockholders | -36.18M | -116.54M | -87.97M | -34.51M |
| NetIncome | -36.18M | -116.54M | -87.97M | -34.51M |
| NetIncomeIncludingNoncontrollingInterests | -36.18M | -116.54M | -87.97M | -34.51M |
| NetIncomeContinuousOperations | -36.18M | -116.54M | -87.97M | -34.51M |
| TaxProvision | 431.00K | 0.00 | 0.00 | -2.35M |
| PretaxIncome | -35.75M | -116.54M | -87.97M | -36.86M |
| OtherIncomeExpense | 34.82M | -73.54M | -48.19M | 7.00K |
| OtherNonOperatingIncomeExpenses | 3.92M | 2.67M | 462.00K | 7.00K |
| SpecialIncomeCharges | 0.00 | -48.65M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 48.65M | 0.00 | |
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | 30.90M | -76.21M | ||
| NetNonOperatingInterestIncomeExpense | 0.00 | |||
| OperatingIncome | -70.58M | -43.00M | -39.78M | -36.87M |
| OperatingExpense | 70.58M | 43.00M | 39.78M | 36.87M |
| ResearchAndDevelopment | 51.96M | 30.31M | 27.08M | 23.73M |
| SellingGeneralAndAdministration | 18.61M | 12.69M | 12.70M | 13.13M |
| GeneralAndAdministrativeExpense | 18.61M | 12.69M | 12.70M | 13.13M |
| OtherGandA | 18.61M | 12.69M | 12.70M | 13.13M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 59.79M | 24.21M | 13.78M | 14.31M |
| ShareIssued | 59.79M | 24.21M | 13.78M | 14.31M |
| TotalDebt | 954.00K | 383.00K | 746.00K | 769.00K |
| TangibleBookValue | 30.06M | -80.87M | 51.80M | 82.96M |
| InvestedCapital | 62.45M | -48.49M | 84.18M | 164.00M |
| WorkingCapital | 132.15M | 52.23M | 53.04M | 83.94M |
| NetTangibleAssets | 85.75M | -25.18M | 51.80M | 82.96M |
| CapitalLeaseObligations | 954.00K | 383.00K | 746.00K | 769.00K |
| CommonStockEquity | 62.45M | -48.49M | 84.18M | 164.00M |
| PreferredStockEquity | 55.69M | 55.69M | ||
| TotalCapitalization | 118.14M | 7.21M | 84.18M | 164.00M |
| TotalEquityGrossMinorityInterest | 118.14M | 7.21M | 84.18M | 164.00M |
| StockholdersEquity | 118.14M | 7.21M | 84.18M | 164.00M |
| GainsLossesNotAffectingRetainedEarnings | 26.00K | 0.00 | ||
| OtherEquityAdjustments | 26.00K | |||
| RetainedEarnings | -355.59M | -319.40M | -202.87M | -114.90M |
| AdditionalPaidInCapital | 417.95M | 270.89M | 287.03M | 278.88M |
| CapitalStock | 55.75M | 55.72M | 14.00K | 14.00K |
| CommonStock | 60.00K | 24.00K | 14.00K | 14.00K |
| PreferredStock | 55.69M | 55.69M | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 59.27M | 81.86M | 8.61M | 6.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 47.69M | 77.96M | 2.13M | 2.15M |
| DerivativeProductLiabilities | 44.87M | 76.21M | 0.00 | |
| NonCurrentDeferredLiabilities | 2.18M | 1.75M | 1.75M | 1.75M |
| NonCurrentDeferredTaxesLiabilities | 2.18M | 1.75M | 1.75M | 1.75M |
| LongTermDebtAndCapitalLeaseObligation | 640.00K | 0.00 | 383.00K | 400.00K |
| LongTermCapitalLeaseObligation | 640.00K | 0.00 | 383.00K | 400.00K |
| CurrentLiabilities | 11.58M | 3.90M | 6.47M | 4.40M |
| CurrentDebtAndCapitalLeaseObligation | 314.00K | 383.00K | 363.00K | 369.00K |
| CurrentCapitalLeaseObligation | 314.00K | 383.00K | 363.00K | 369.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.60M | 2.00M | 1.91M | 1.51M |
| PayablesAndAccruedExpenses | 9.66M | 1.51M | 4.20M | 2.52M |
| CurrentAccruedExpenses | 3.83M | 542.00K | 2.00M | 704.00K |
| Payables | 5.83M | 967.00K | 2.20M | 1.81M |
| AccountsPayable | 5.83M | 967.00K | 2.20M | 1.81M |
| TotalAssets | 177.41M | 89.07M | 92.79M | 170.55M |
| TotalNonCurrentAssets | 33.67M | 32.94M | 33.27M | 82.20M |
| OtherNonCurrentAssets | 363.00K | 186.00K | 150.00K | 400.00K |
| GoodwillAndOtherIntangibleAssets | 32.39M | 32.39M | 32.39M | 81.03M |
| OtherIntangibleAssets | 32.39M | 32.39M | 32.39M | 32.39M |
| Goodwill | 0.00 | 48.65M | ||
| NetPPE | 926.00K | 365.00K | 739.00K | 768.00K |
| GrossPPE | 926.00K | 365.00K | 739.00K | 768.00K |
| OtherProperties | 365.00K | 739.00K | 768.00K | |
| BuildingsAndImprovements | 926.00K | 365.00K | 739.00K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 143.73M | 56.13M | 59.52M | 88.35M |
| OtherCurrentAssets | 729.00K | 90.00K | 28.00K | 34.00K |
| PrepaidAssets | 2.82M | 4.94M | 3.08M | 3.48M |
| Receivables | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 140.18M | 51.10M | 56.41M | 84.83M |
| OtherShortTermInvestments | 119.63M | 46.49M | 0.00 | |
| CashAndCashEquivalents | 20.55M | 4.61M | 56.41M | 84.83M |
| CashEquivalents | 9.30M | 9.30M | ||
| CashFinancial | 47.11M | 75.53M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -47.27M | -39.53M | -28.42M | -28.91M |
| IssuanceOfCapitalStock | 133.31M | 33.02M | 0.00 | 0.00 |
| EndCashPosition | 20.55M | 4.61M | 56.41M | 84.83M |
| BeginningCashPosition | 4.61M | 56.41M | 84.83M | 114.19M |
| ChangesInCash | 15.94M | -51.80M | -28.42M | -29.36M |
| FinancingCashFlow | 133.52M | 33.02M | 0.00 | -449.00K |
| CashFlowFromContinuingFinancingActivities | 133.52M | 33.02M | 0.00 | -449.00K |
| NetOtherFinancingCharges | -450.00K | |||
| ProceedsFromStockOptionExercised | 215.00K | 0.00 | 0.00 | 1.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 133.31M | 33.02M | 0.00 | 0.00 |
| CommonStockIssuance | 133.31M | 33.02M | 0.00 | 0.00 |
| InvestingCashFlow | -70.31M | -45.29M | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | -70.31M | -45.29M | 0.00 | 0.00 |
| NetInvestmentPurchaseAndSale | -70.31M | -45.29M | 0.00 | |
| SaleOfInvestment | 85.82M | 33.00M | 0.00 | |
| PurchaseOfInvestment | -156.13M | -78.29M | 0.00 | |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| OperatingCashFlow | -47.27M | -39.53M | -28.42M | -28.91M |
| CashFlowFromContinuingOperatingActivities | -47.27M | -39.53M | -28.42M | -28.91M |
| ChangeInWorkingCapital | 8.71M | -4.92M | 2.37M | -152.00K |
| ChangeInOtherCurrentLiabilities | -339.00K | -363.00K | -367.00K | -200.00K |
| ChangeInPayablesAndAccruedExpense | 7.75M | -2.60M | 2.08M | 2.14M |
| ChangeInPayable | 7.75M | -2.60M | 2.08M | |
| ChangeInAccountPayable | 7.75M | -2.60M | 2.08M | |
| ChangeInPrepaidAssets | 1.30M | -1.95M | 654.00K | -2.10M |
| OtherNonCashItems | -10.00K | |||
| StockBasedCompensation | 13.12M | 6.54M | 8.15M | 7.90M |
| AssetImpairmentCharge | 0.00 | 48.65M | 0.00 | |
| AmortizationOfSecurities | -2.80M | -1.20M | 0.00 | |
| DeferredTax | 431.00K | 0.00 | 0.00 | -2.35M |
| DeferredIncomeTax | 431.00K | 0.00 | 0.00 | -2.35M |
| DepreciationAmortizationDepletion | 359.00K | 374.00K | 373.00K | 195.00K |
| DepreciationAndAmortization | 359.00K | 374.00K | 373.00K | 195.00K |
| Depreciation | 359.00K | 374.00K | 373.00K | 195.00K |
| OperatingGainsLosses | -30.90M | 76.21M | ||
| GainLossOnInvestmentSecurities | -30.90M | 76.21M | ||
| NetIncomeFromContinuingOperations | -36.18M | -116.54M | -87.97M | -34.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ELDN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|